These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 36123506)

  • 1. Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.
    Zhao L; Wang Y; Tian T; Rao X; Dong W; Zhang J; Yang Y; Tao Q; Peng F; Shen C; Wang S; Liu H; Zeng X; Zhou W
    Hepatol Int; 2022 Dec; 16(6):1339-1352. PubMed ID: 36123506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
    An J; Kim D; Oh B; Oh YJ; Song J; Park N; Kim HI; Kang HJ; Oh JH; Kim W; Lee E; Sung CO; Song GW; Kim DG; Yu E; Letouzé E; Zucman-Rossi J; Lee HC; Shim JH
    Hepatology; 2022 Apr; 75(4):997-1011. PubMed ID: 34478159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
    Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
    Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
    J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus-related intrahepatic cholangiocarcinoma originates from hepatocytes.
    Song Z; Lin S; Wu X; Ren X; Wu Y; Wen H; Qian B; Lin H; Huang Y; Zhao C; Wang N; Huang Y; Peng B; Li X; Peng H; Shen S
    Hepatol Int; 2023 Oct; 17(5):1300-1317. PubMed ID: 37368186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of adeno-associated virus (AAV) into the genomes of most Thai and Mongolian liver cancer patients does not induce oncogenesis.
    Schäffer AA; Dominguez DA; Chapman LM; Gertz EM; Budhu A; Forgues M; Chaisaingmongkol J; Rabibhadana S; Pupacdi B; Wu X; Bayarsaikhan E; Harris CC; Ruchirawat M; Ruppin E; Wang XW
    BMC Genomics; 2021 Nov; 22(1):814. PubMed ID: 34763675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis.
    Xue TC; Zhang BH; Ye SL; Ren ZG
    Tumour Biol; 2015 Aug; 36(8):5891-9. PubMed ID: 25712376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers.
    Wakizaka K; Yokoo H; Kamiyama T; Ohira M; Kato K; Fujii Y; Sugiyama K; Okada N; Ohata T; Nagatsu A; Shimada S; Orimo T; Kamachi H; Taketomi A
    J Gastroenterol Hepatol; 2019 Jun; 34(6):1074-1080. PubMed ID: 30462849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.
    Wang AQ; Zheng YC; Du J; Zhu CP; Huang HC; Wang SS; Wu LC; Wan XS; Zhang HH; Miao RY; Sang XT; Zhao HT
    World J Gastroenterol; 2016 May; 22(18):4459-65. PubMed ID: 27182157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.
    Zhao Q; Yu WL; Lu XY; Dong H; Gu YJ; Sheng X; Cong WM; Wu MC
    Chin J Cancer; 2016 Aug; 35(1):82. PubMed ID: 27552844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the distinct immune microenvironments between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Jiang S; Lu H; Pan Y; Yang A; Aikemu A; Li H; Hao R; Huang Q; Qi X; Tao Z; Wu Y; Quan C; Zhou G; Lu Y
    Cancer Lett; 2024 Apr; 588():216799. PubMed ID: 38479553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas.
    Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Yamamoto Y; Ashida R; Ohgi K; Nagashima T; Yamaguchi K
    J Hepatobiliary Pancreat Sci; 2023 Mar; 30(3):269-282. PubMed ID: 35918906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance.
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2017 Feb; 70(3):423-434. PubMed ID: 27634656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type.
    Chen J; He J; Deng M; Wu HY; Shi J; Mao L; Sun Q; Tang M; Fan XS; Qiu YD; Huang Q
    Hum Pathol; 2017 Jun; 64():118-127. PubMed ID: 28431889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study.
    Zhou YW; Li QF; Chen YY; Wang K; Pu D; Chen XR; Li CH; Jiang L; Wang Y; Li Q; Yang Y; Gou HF; Bi F; Liu JY; Chen Y; Qiu M
    Eur J Surg Oncol; 2022 Jul; 48(7):1559-1566. PubMed ID: 35115213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers.
    Lee CH; Hsieh SY; Chang CJ; Lin YJ
    J Gastroenterol Hepatol; 2013 Jan; 28(1):122-7. PubMed ID: 23034166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival outcomes of combined hepatocellular-cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: A SEER population-based cohort study.
    Yang Z; Shi G
    Cancer Med; 2022 Feb; 11(3):692-704. PubMed ID: 34862762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.
    Gao Q; Zhao YJ; Wang XY; Guo WJ; Gao S; Wei L; Shi JY; Shi GM; Wang ZC; Zhang YN; Shi YH; Ding J; Ding ZB; Ke AW; Dai Z; Wu FZ; Wang H; Qiu ZP; Chen ZA; Zhang ZF; Qiu SJ; Zhou J; He XH; Fan J
    Gastroenterology; 2014 May; 146(5):1397-407. PubMed ID: 24503127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review).
    Yang R; Song Y; Shakoor K; Yi W; Peng C; Liu S
    Mol Med Rep; 2022 May; 25(5):. PubMed ID: 35302174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
    Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
    Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.